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Introduction {#jdv14703-sec-0005}
============

Non‐melanoma skin cancer (NMSC) is a collective term that describes several forms of cutaneous neoplasia that do not stem from melanocytes. Among these neoplasia, squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) are the most common forms that are considered the most common malignancies in the Western world.[1](#jdv14703-bib-0001){ref-type="ref"} Thus, these cancers represent a major healthcare problem due to the large group of affected patients. In Germany, the incidence was 119 of 100 000 for women and 145 of 100 000 for men in a recent screening period, which makes NMSC 6.5 times more common than malignant melanoma.[2](#jdv14703-bib-0002){ref-type="ref"} Among the affected patients, 53% are male, and the age‐standardised incidence is as high as 108.2 per 100 000 (European standard) and thus in the incidence range of prostate cancer.[3](#jdv14703-bib-0003){ref-type="ref"} In women, the incidence rate is 77.8 per 100 000 (European standard), which ranks between breast cancer (123.8 per 100 000) and colorectal cancer (38.0 per 100 000).[3](#jdv14703-bib-0003){ref-type="ref"} Identified risk factors for the development of NMSC are age (strong increase in male patients over 60), fair skin phototype (Fitzpatrick I and II) and (cumulative) UV‐exposure.

A further risk factor, particularly for SCC, is the presence of actinic keratosis (AK). These epidermal neoplastic lesions have been described as epidermal *carcinoma‐in‐situ*.[4](#jdv14703-bib-0004){ref-type="ref"}, [5](#jdv14703-bib-0005){ref-type="ref"} A large cohort analysis revealed that 65% of all primary SCCs occurred in lesions previously clinically diagnosed as AKs.[6](#jdv14703-bib-0006){ref-type="ref"} Thus, it is reasonable to include AK in the wider scope of NMSC, whenever prognostic or epidemiological considerations are made. AK is, just as both SCC and BCC, an ultraviolet‐light‐induced lesion of the skin that may progress to invasive carcinoma.[7](#jdv14703-bib-0007){ref-type="ref"}, [8](#jdv14703-bib-0008){ref-type="ref"} It is the most common lesion with malignant potential. AK is mostly seen in Caucasians on skin areas of long‐term sun exposure.[9](#jdv14703-bib-0009){ref-type="ref"} Epidemiological data show a high occurrence rate of AK, which is even higher in regions with higher ultraviolet exposure. For the United States, the prevalence ranges from 11% to 26%,[9](#jdv14703-bib-0009){ref-type="ref"} while in Australia, it ranges from 40% to 60%.[10](#jdv14703-bib-0010){ref-type="ref"} In Europe, a prevalence of 15% in men and 6% in women has been documented.[11](#jdv14703-bib-0011){ref-type="ref"} Over the age of 70 years, 34% of men and 18% of women were found to have AK.[11](#jdv14703-bib-0011){ref-type="ref"} While this represents a massive disease burden on society, NMSC and AK tend to involve lower morbidity and mortality than malignant melanoma[12](#jdv14703-bib-0012){ref-type="ref"} and can be treated or managed successfully in many cases. Still, treatment of BCC and SCC routinely involves surgery and --given the predominant occurrence of these cancers in sun‐exposed areas such as the face and scalp --surgical measures can be gruelling, stressful and cosmetically unfavourable for the patients.[13](#jdv14703-bib-0013){ref-type="ref"}

The numerous therapeutic options available for the treatment of AK[14](#jdv14703-bib-0014){ref-type="ref"} are regarded as a valuable approach to SCC prevention.[15](#jdv14703-bib-0015){ref-type="ref"} There is reason to assume that NMSC goes along with a reduction in health‐related quality of life (QL), and various studies have tried to quantify this reduction with various patient‐reported outcome measures (PROMs).[13](#jdv14703-bib-0013){ref-type="ref"} Still, no robust data set is available for German‐speaking countries. So far, some groups have used standard dermatological instruments such as DLQI[16](#jdv14703-bib-0016){ref-type="ref"}, [17](#jdv14703-bib-0017){ref-type="ref"}, [18](#jdv14703-bib-0018){ref-type="ref"} or Skindex‐16,[19](#jdv14703-bib-0019){ref-type="ref"}, [20](#jdv14703-bib-0020){ref-type="ref"} others developed specialised instruments for patients with NMSC[21](#jdv14703-bib-0021){ref-type="ref"} and AK[22](#jdv14703-bib-0022){ref-type="ref"}, [23](#jdv14703-bib-0023){ref-type="ref"} and validated them in different populations.[24](#jdv14703-bib-0024){ref-type="ref"}, [25](#jdv14703-bib-0025){ref-type="ref"} While such an approach may be useful for assessing the disease burden of individual NMSC subtypes, AK and NMSC represent a clinical continuum. It is thus worthwhile investigating, how QL is affected in a cross‐sectional selection of patients with different stages of epidermal neoplasia in the sense of disease progression. Additionally, in their recent structured review on PROMs, authors from the United Kingdom expressed the need to analyse NMSC QL using a common standardised instrument and recommended the implementation of EQ‐5D in this disease spectrum.[26](#jdv14703-bib-0026){ref-type="ref"}, [27](#jdv14703-bib-0027){ref-type="ref"} The EQ Index in particular represents a very robust outcome measure[28](#jdv14703-bib-0028){ref-type="ref"} that can also be implemented in the calculation of quality‐adjusted life years (QALYs) in future health economic evaluations of NMSC treatments.[29](#jdv14703-bib-0029){ref-type="ref"}

This study included patients with NMSC and AK and was designed to elucidate whether the proposed disease continuum is also accompanied by impairment in QL.

Methods {#jdv14703-sec-0006}
=======

Study design {#jdv14703-sec-0007}
------------

This prospective, cross‐sectional, German‐wide, multicentre study was carried out in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the University of Regensburg (Institutional Review Board Number 15‐160‐0036). Between October 2015 and February 2016, 1194 consecutive patients with NMSC and AK treated at 29 local medical practices or hospitals were recruited. Inclusion criteria were as follows: age ≥18 years, current diagnosis of NMSC (BCC or SCC) and/or AK, and informed consent. Ten patients did not meet the inclusion criteria and were excluded from the analyses, which resulted in a total number of 1184 patients.

Documentation and procedure {#jdv14703-sec-0008}
---------------------------

Patients filled in the EQ‐5D‐5L (EuroQol 5 dimensions 5 levels) to report their degree of QL. The EQ‐5D‐5L is a reliable and valid tool used in patient and general population groups in various countries.[30](#jdv14703-bib-0030){ref-type="ref"}, [31](#jdv14703-bib-0031){ref-type="ref"} The questionnaire consists of a descriptive system including five dimensions (mobility, self‐care, usual activities, pain and anxiety), each rated on five levels (no problem, slight problems, moderate problems, severe problems and extreme problems), and a visual analogue scale (VAS) assessing the current health status on a scale ranging from 0 (worst) to 100 (best).[32](#jdv14703-bib-0032){ref-type="ref"} The developers of the EQ‐5D‐5L emphasise the need to use both parts of the questionnaire.[32](#jdv14703-bib-0032){ref-type="ref"} According to the guidelines of the EuroQol Group,[32](#jdv14703-bib-0032){ref-type="ref"} the five dimensions were transformed into individual health status profiles (range = 11111 \[best\] to 55555 \[worst\]) and then converted into German‐specific EQ Indices (range = −0.21 \[worst\] to 1.00 \[best\]) based on time trade‐off (TTO) valuation technique. Each possible health status profile will be weighted differently based on country‐specific preference values of the general population. Country‐specific value sets make the EQ Indices comparable across countries and allow for detecting differences due to social--cultural values and economic systems.[30](#jdv14703-bib-0030){ref-type="ref"}, [31](#jdv14703-bib-0031){ref-type="ref"}, [33](#jdv14703-bib-0033){ref-type="ref"} This one‐dimensional utility index can be used to calculate QALYs in subsequent health economic analyses.

Patients were asked to provide information regarding basic demographic variables (age, sex, marital status and number of children, educational level and current professional activity). Educational level was classified as low, medium or high according to the International Standard Classification of Education (ISCED).[34](#jdv14703-bib-0034){ref-type="ref"}

Clinicians in charge of treating patients provided information on diagnosis, number of lesions, treatment period (in months) and current and past treatments. The treatments were recorded as follows: physical (excision, excision with histographic control of resection margin, curettage and/or electrodesiccation, laser therapy, radiotherapy and cryosurgery), drug (5% 5‐FU, imiquimod, 0.5% 5‐FU/10% salicylic acid‐lacquer, 3% diclofenac‐sodium/hyaluronic acid gel and ingenol mebutate), photodynamic therapy as well as watch and wait.

Statistical analyses {#jdv14703-sec-0009}
--------------------

Descriptive analyses (frequencies \[*n*\], percentages \[%\], mean \[*m*\], standard deviation \[SD\], 95% confidence interval \[95% CI\], median \[med\] and quartiles \[Q1/Q3\]) were used to describe sociodemographic, clinical and QL data. Normal distribution of continuous variables was examined with the Shapiro--Wilk test.

Spearman\'s rank correlation was used to assess the correlation between EQ Index and EQ VAS. To examine whether a proposed disease continuum is also accompanied by impairment in QL (EQ Index and EQ VAS), two‐way ANCOVAs (analyses of covariance) were conducted. Age and sex were included in the model as both factors were consistently found to be related with QL (e.g.[35](#jdv14703-bib-0035){ref-type="ref"}). Two different ANCOVA models were used to examine QL in patients with different diagnosis. In the first model, patients were categorised according their diagnosis as follows: (i) AK (single diagnosis of AK), (ii) BCC (including single BCC diagnosis as well as combined diagnoses of AK plus BCC), (iii) SCC (including single SCC diagnosis as well as combined diagnoses of AK plus SCC and (iv) BCC plus SCC (including combined diagnoses of BCC plus SCC as well as combined diagnoses of AK plus BCC plus SCC). To examine estimates from cross‐sectional data whether disease progression results in higher QL impairment, a second model was used with the following patient groups: (i) single diagnosis of AK, (ii) single diagnosis of SCC, and (iii) combined diagnoses of AK plus SCC. To account for the non‐normal distribution of the QL data, calculations were repeated using RANCOVAs (analyses of covariance‐based ranks of QL data),[36](#jdv14703-bib-0036){ref-type="ref"} which yielded comparable results (results not reported, but available upon request).

The programme IBM SPSS Statistics 24 was used for all statistical analyses. The significance level was set at *P* ~(two‐sided)~ ≤ 0.050.

Results {#jdv14703-sec-0010}
=======

Patient characteristics {#jdv14703-sec-0011}
-----------------------

*Sociodemographic data* (Table [1](#jdv14703-tbl-0001){ref-type="table"}). The median age was 74 years (Q1/Q3 = 66/79 years, range = 32 to 95 years). The majority of the patients were male (61%), had a low educational level (64%), and were retired (73%).

###### 

Sociodemographic data

  *N* = 1184                                        Med   Q1/Q3   Range
  ------------------------------------------------- ----- ------- --------
  **Age** [a](#jdv14703-note-0003){ref-type="fn"}   74    66/79   32--95
                                                    *n*   \%      
  **Sex**                                                         
  Male                                              726   61.3    
  Female                                            433   36.6    
  Missing value                                     25    2.1     
  **Marital status**                                              
  Married/living in permanent relationship          813   69.2    
  Single/divorced/widowed                           354   29.9    
  Missing value                                     11    0.9     
  **Children**                                                    
  No                                                481   59.4    
  Yes (med = 2, Q1/Q3 = 2/2)                        703   40.6    1--14
  **Educational level**                                           
  Low                                               760   64.2    
  Medium                                            140   11.8    
  High                                              235   19.8    
  Missing value                                     49    4.1     
  **Professional activity**                                       
  Student/trainee/job seeker                        4     0.4     
  Employer                                          116   9.8     
  Worker                                            19    1.6     
  Civil servant                                     28    2.4     
  Freelancer                                        64    5.4     
  Housewife/househusband                            50    4.2     
  Pensioner                                         863   72.9    
  Missing value                                     40    3.3     

Missing values for *n* = 21 (1.8%).
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### Clinical data {#jdv14703-sec-0012}

The diagnoses were documented as follows (multiple answers were permissible): 73% AK, 49% BCC and 17% SCC. 66% had a single diagnosis, 28% two different diagnoses and 6% three different diagnoses. The majority of the lesions were located on the head (86%). Table [2](#jdv14703-tbl-0002){ref-type="table"} presents detailed clinical data. The median treatment period was 49 months (Q1/Q3 = 16/101 months, range = 0 to 308 months, *n* = 1105). Table [3](#jdv14703-tbl-0003){ref-type="table"} presents treatments broken down by diagnoses.

###### 

Clinical data

                                                   *n*    \%
  ------------------------------------------------ ------ ------
  **Diagnosis** (multiple answers)                        
  Actinic keratosis                                869    73.4
  Basal cell carcinoma                             578    48.8
  Superficial                                      282    23.6
  Nodular                                          231    19.5
  Other                                            82     6.9
  Missing value                                    64     5.4
  Squamous cell carcinoma                          204    17.2
  **Number of diagnosis**                                 
  1                                                785    66.3
  2                                                331    28.0
  3                                                68     5.7
  **Number of lesions**                                   
  Actinic keratosis                                869    
  1--3                                             329    37.9
  4--6                                             232    26.7
  \>6/field                                        271    31.2
  Missing value                                    37     4.3
  Basal cell carcinoma                             578    
  1--3                                             429    74.2
  4--6                                             34     5.9
  \>6                                              28     4.8
  Missing value                                    87     15.1
  Squamous cell carcinoma                          204    
  1--3                                             171    83.8
  4--6                                             9      4.4
  \>6                                              4      2.0
  Missing value                                    20     9.8
  **Localisation of lesions** (multiple answers)          
  Head                                             1014   85.6
  Trunk                                            180    15.2
  Extremities                                      218    18.4
  Missing value                                    42     3.5
  Actinic keratosis                                869    
  Head                                             780    89.8
  Trunk                                            40     4.6
  Extremities                                      93     10.7
  Missing value                                    53     6.1
  Basal cell carcinoma                             578    
  Head                                             405    70.1
  Trunk                                            146    25.3
  Extremities                                      111    19.2
  Missing value                                    19     3.3
  Squamous cell carcinoma                          204    
  Head                                             155    76.0
  Trunk                                            9      4.4
  Extremities                                      44     21.6
  Missing value                                    10     4.9
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###### 

Treatment types (multiple answers)

                                                           All    Actinic keratosis   Basal cell carcinoma   Squamous cell carcinoma                      
  -------------------------------------------------------- ------ ------------------- ---------------------- ------------------------- ----- ------ ----- ------
  **Current treatment**                                    *n*    \%                  *n*                    \%                        *n*   \%     *n*   \%
  No/no information                                        114    9.6                 88                     10.1                      188   32.5   92    45.1
  Yes                                                      1070   90.4                781                    89.9                      390   67.5   112   54.9
  Physical therapy                                         661    55.8                351                    40.4                      329   56.9   92    45.1
  Excision                                                 246    20.8                49                     5.6                       179   31.0   50    24.5
  Excision with histographic control of resection margin   188    15.9                16                     1.8                       149   25.8   42    20.6
  Curettage                                                84     7.1                 78                     9.0                       12    2.1    1     0.5
  Laser                                                    53     4.5                 50                     5.8                       3     0.5    0     0
  Radiotherapy                                             2      0.2                 2                      0.2                       0     0      0     0
  Cryosurgery                                              226    19.1                219                    25.2                      13    2.2    1     0.5
  Drug therapy                                             251    21.2                245                    28.2                      5     0.9    2     1.0
  5‐FU                                                     61     5.2                 60                     6.9                       0     0      1     0.5
  Imiquimod                                                29     2.4                 26                     3.0                       3     0.5    0     0
  5‐FU/salicylic acid‐lacquer                              49     4.1                 48                     5.5                       1     0.2    0     0
  Diclofenac‐sodium/hyaluronic acid gel                    114    9.6                 111                    12.8                      2     0.3    1     0.5
  Ingenol mebutate                                         27     2.3                 27                     3.1                       0     0      0     0
  Photodynamic therapy                                     342    28.9                315                    36.2                      41    7.1    2     1.0
  Watch and wait                                           101    8.5                 54                     6.2                       42    7.3    18    8.8
  **Past treatment**                                                                                                                                      
  No/no information                                        389    32.9                231                    26.6                      269   46.5   88    43.1
  Yes                                                      795    67.1                638                    73.4                      309   53.5   116   56.9
  Physical therapy                                         599    50.6                397                    45.7                      288   49.8   112   54.9
  Excision                                                 257    21.7                99                     11.4                      154   26.6   54    26.5
  Excision with histographic control of resection margin   183    15.5                26                     3.0                       136   23.5   58    28.4
  Curettage                                                140    11.8                125                    14.4                      20    3.5    7     3.4
  Laser                                                    63     5.3                 58                     6.7                       4     0.7    1     0.5
  Radiotherapy                                             5      0.4                 2                      0.2                       0     0      3     1.5
  Cryosurgery                                              246    20.8                226                    26.0                      26    4.5    10    4.9
  Drug therapy                                             298    25.2                283                    32.6                      14    2.4    3     1.5
  5‐FU                                                     78     6.6                 76                     8.7                       1     0.2    1     0.5
  Imiquimod                                                81     6.8                 70                     8.1                       11    1.9    1     0.5
  5‐FU/salicyclic acid‐lacquer                             52     4.4                 52                     6.0                       0     0      0     0
  diclofenac‐sodium/hyaluronic acid gel                    201    17.0                196                    22.6                      4     0.7    2     1.0
  Ingenol mebutate                                         47     4.0                 46                     5.3                       2     0.3    1     0.5
  Photodynamic therapy                                     274    23.1                255                    29.3                      33    5.7    6     2.9
  Watch and wait                                           53     4.5                 43                     4.9                       14    2.4    1     0.5

John Wiley & Sons, Ltd

### QL data {#jdv14703-sec-0013}

Four hundred and forty‐three (38%) of the patients reported no problems in any of the five dimensions of the EQ‐5D‐5L (health status profile = 11111). Table [4](#jdv14703-tbl-0004){ref-type="table"} presents the distribution of the EQ‐5D‐5L dimensions by levels. The median EQ Index was 0.91 (Q1/Q3 = 0.83/1.00, *m* = 0.87, SD = 0.18, range = −0.21 to 1.00, *n* = 1162) and the median EQ VAS was 90 (Q1/Q3 = 65/90, *m* = 75, SD = 19, range = 3 to 100, *n* = 1175). There exists a strong and positive association between EQ Index and EQ VAS (*r* ~s(1154)~ = 0.65, *P* \< 0.001).

###### 

Description of the EQ‐5D‐5L

  *n* = 1162[a](#jdv14703-note-0004){ref-type="fn"}   Mobility   Self‐care   Usual activities   Pain   Anxiety                             
  --------------------------------------------------- ---------- ----------- ------------------ ------ --------- ------ ----- ------ ----- ------
  No problem                                          759        65.3        966                83.1   834       71.8   590   50.8   819   70.5
  Slight problems                                     215        18.5        107                9.2    201       17.3   341   29.3   228   19.6
  Moderate problems                                   112        9.6         58                 5.0    76        6.5    151   13.3   76    6.5
  Severe problems                                     67         5.8         24                 2.1    41        3.5    59    5.1    35    3.0
  Extreme problems                                    9          0.8         7                  0.6    10        0.9    18    1.5    4     0.3

Missing values for *n* = 22 (1.9%).
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Association between quality of life and diagnosis {#jdv14703-sec-0014}
-------------------------------------------------

### Model 1 {#jdv14703-sec-0015}

To assess QL differences between patients with different NMSC diagnoses and AK, model 1 made the following comparisons: AK vs. BCC vs. SCC vs. BCC plus SCC.

Using the EQ Index as a dependent variable, model 1 was statistically significant (*F* ~(8/1134)~ = 18.322, *P* \< 0.001). Main effects were found for diagnosis (*F* ~(3/1134)~ = 5.687, *P* = 0.001), sex (*F* ~(1/1134)~ = 13.985, *P* \< 0.001) and age (*F* ~(1/1134)~ = 102.743, *P* \< 0.001). Patients with BCC plus SCC reported significantly less QL than patients with AK (*P* = 0.002, 9%) (Fig. [1](#jdv14703-fig-0001){ref-type="fig"}a). Men (*m* = 0.88, 95% CI = 0.86/0.90) had a significantly higher mean EQ Index than women (*m* = 0.82, 95% CI = 0.80/0.85, *P* \< 0.001). There was no interaction effect between diagnosis and sex (*F* ~(3/1134)~ = 2.469, *P* = 0.061).

![Quality of life differences (adjusted for age) between diagnoses. QL was measured by EQ Index and EQ VAS of the EQ‐5D‐5L. ANCOVA model 1 compares QL between patients with AK and NMSC diagnoses; Model 2 compares in detail QL differences between patients with AK and SCC to estimate whether disease progression results in higher QL impairment. All corrected ANCOVA models were significant: 1a *F* ~(8/1134)~ = 18.322, *P* \< 0.001, 1b *F* ~(8/1148)~ = 14.402, *P* \< 0.001, 1c *F* ~(6/580)~ = 11.931, *P* \< 0.001, and 1d *F* ~(6/589)~ = 7.227, *P* \< 0.001. Based on the estimated marginal means of QL (adjusted for age) of patients with AK,QL decrease (in percentage) for patients with NMSC diagnoses is presented along with significant levels: \* *P* ≤ 0.050, \*\* *P* ≤ 0.010, \*\*\* *P* ≤ 0.001.](JDV-32-1138-g001){#jdv14703-fig-0001}

Using EQ VAS as a dependent variable, model 1 was also statistically significant (*F* ~(8/1148)~ = 14.402, *P* \< 0.001). Main effects were found for diagnosis (*F* ~(3/1134)~ = 6.496, *P* \< 0.001) and age (*F* ~(1/1148)~ = 74.510, *P* \< 0.001). Patients with a single AK diagnosis had significantly higher mean EQ VAS than patients with BCC (*P* = 0.013, 4%), SCC (*P* = 0.040, 6%) and BCC plus SCC (*P* = 0.004, 9%) (Fig. [1](#jdv14703-fig-0001){ref-type="fig"}b). There was no main effect for sex (*F* ~(1/1148)~ = 0.377, *P* = 0.539), and no interaction effect between diagnosis and sex (*F* ~(3/1148)~ = 0.047, *P* = 0.986).

### Model 2 {#jdv14703-sec-0016}

The second model examined the effects of disease progression in more detail by comparing three groups of patients: single diagnosis of AK, single diagnosis of SCC and combined diagnosis of AK plus SCC.

Using the EQ Index as a dependent variable, model 2 was statistically significant (*F* ~(6/580)~ = 11.931, *P* \< 0.001). Main effects were found for diagnosis (*F* ~(2/580)~ = 6.356, *P* = 0.002) and age (*F* ~(1/580)~ = 46.134, *P* \< 0.001). Patients with AK plus SCC reported significantly less QL than patients with AK (*P* = 0.002, 7%) (Fig. [1](#jdv14703-fig-0001){ref-type="fig"}c). There was no main effect for sex (*F* ~(1/580)~ = 0.929, *P* = 0.335), and no interaction between diagnosis and sex (*F* ~(2/1134)~ = 1.339, *P* = 0.263).

Using the EQ VAS as a dependent variable, model 2 was statistically significant (*F* ~(6/589)~ = 7.227, *P* \< 0.001). Main effects were found for diagnosis (*F* ~(2/589)~ = 4.482, *P* = 0.012) and age (*F* ~(1/589)~ = 26.691, *P* \< 0.001). Patients with AK plus SCC reported significantly less QL than patients with AK (*P* = 0.011, 7%) (Fig. [1](#jdv14703-fig-0001){ref-type="fig"}d). There was no main effect for sex (*F* ~(1/589)~ = 0.025, *P* = 0.874), and no interaction between diagnosis and sex (*F* ~(2/589)~ = 0.081, *P* = 0.922).

Table [5](#jdv14703-tbl-0005){ref-type="table"} presents medians and quartiles of QL values (not adjusted for age) separated for the fixed factors of both models.

###### 

Unadjusted descriptive statistics of QL measures broken down by diagnosis and sex

  Groups               EQ INDEX   EQ VAS                                                                                                                                                                             
  -------------------- ---------- ------------------ ------------------ ------------------ ------------------ ------------------ ------------------ ------------ ------------ ------------ ------------ ------------ ------------
  **ANCOVA model 1**   AK         468                1.00 (0.83/1.00)   308                1.00 (0.83/1.00)   160                0.92 (0.83/1.00)   477          80 (70/90)   312          80 (70/90)   165          80 (70/92)
  BCC                  472        0.91 (0.83/1.00)   268                0.91 (0.83/1.00)   204                0.91 (0.81/1.00)   477                80 (65/90)   272          80 (65/90)   205          80 (65/90)   
  SCC                  112        0.91 (0.72/1.00)   73                 0.91 (0.78/1.00)   39                 0.86 (0.68/1.00)   112                75 (51/90)   72           77 (55/90)   40           72 (50/86)   
  BCC + SCC            82         0.89 (0.72/1.00)   62                 0.91 (0.75/1.00)   20                 0.81 (0.54/0.98)   82                 70 (50/82)   61           70 (50/81)   21           70 (55/88)   
                                                                                                                                                                                                                     
  **ANCOVA model 2**   AK         468                1.00 (0.83/1.00)   308                1.00 (0.83/1.00)   160                0.92 (0.83/1.00)   477          80 (70/90)   312          80 (70/90)   165          80 (70/92)
  SCC                  32         0.91 (0.84/1.00)   20                 0.91 (0.83/1.00)   12                 0.91 (0.87/1.00)   31                 80 (60/90)   18           80 (58/90)   13           80 (55/90)   
  AK+SCC               80         0.91 (0.70/1.00)   53                 0.91 (0.74/1.00)   27                 0.74 (0.55/0.92)   81                 75 (50/90)   54           75 (54/90)   27           70 (50/85)   
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Discussion {#jdv14703-sec-0017}
==========

Only in recent years have PROMs received increasing recognition in the assessment of the burden of benign and malignant cutaneous tumours.[37](#jdv14703-bib-0037){ref-type="ref"} NMSC in all their different manifestations affect a substantial proportion of the general public, especially in the second half of life.[8](#jdv14703-bib-0008){ref-type="ref"}, [38](#jdv14703-bib-0038){ref-type="ref"} Mortality with these conditions is generally low, except for invasive SCC, which has a disease‐specific death risk of 2%.[39](#jdv14703-bib-0039){ref-type="ref"} Still, the different forms of NMSC may impact patient well‐being by being cosmetically unfavourable or even disfiguring and by showing locally destructive growth patterns. In addition to that, there is a continuum from AK to invasive disease (SCC).[7](#jdv14703-bib-0007){ref-type="ref"}, [8](#jdv14703-bib-0008){ref-type="ref"}, [40](#jdv14703-bib-0040){ref-type="ref"}, [41](#jdv14703-bib-0041){ref-type="ref"} Thus, part of the perceived burden may be patient insecurity about their prognosis and its progression. However, in the absence of comparable data and representative studies, it is difficult to determine how far a diagnosis of NMSC and/or AK might influence the life of patients. Thus, we have designed such a study as a non‐interventional, prospective, cross‐sectional study in the context of healthcare research in patients with NMSC and AK in Germany. The EQ‐5D‐5L questionnaire was chosen for its robustness and cross‐cultural applicability and its further use for pharmacoeconomic analyses. The population‐based EQ Index is used for these pharmacoeconomic analyses, whereas the EQ VAS represents patient--individual self‐assessment.[30](#jdv14703-bib-0030){ref-type="ref"} In the present study, the EQ‐5D‐5L proved its sensitivity to discern between groups of patients with different levels of disease progression. Nevertheless, some absolute values obtained in the present study population (e.g. med = 0.91 for the EQ Index, med = 90 for the EQ VAS, perfect health status profile of 11 111 in 38% of the patients) indicate that the EQ‐5D‐5L is still prone to ceiling effects.

So far, very few studies exist that report utilities for NMSC. However, patient groups in these studies were small (*n* = 8 to 41)[19](#jdv14703-bib-0019){ref-type="ref"}, [42](#jdv14703-bib-0042){ref-type="ref"}, [43](#jdv14703-bib-0043){ref-type="ref"} and the used tools were heterogeneous (for a review see[13](#jdv14703-bib-0013){ref-type="ref"}). In the present study, the average, age‐adjusted EQ Index was 0.87 for patients with BCC (*n* = 472) and 0.84 for patients with SCC (*n* = 112). Especially for AK, data on utilities are sparse. Pharmacoeconomic calculations (e.g.[29](#jdv14703-bib-0029){ref-type="ref"}, [44](#jdv14703-bib-0044){ref-type="ref"}, [45](#jdv14703-bib-0045){ref-type="ref"}) using either standard gamble or TTO methodology resulted in utilities of 0.99 and 0.98.[46](#jdv14703-bib-0046){ref-type="ref"}, [47](#jdv14703-bib-0047){ref-type="ref"} However, these two studies included a total number of 25 patients and were not specific for AK but for a broad variety of dermatological conditions. A standardised method using EQ‐5D‐5L was recently published by a research group from Denmark and Sweden.[48](#jdv14703-bib-0048){ref-type="ref"} In total, 312 patients with AK were included in this study. The reported outcomes were as follows: EQ Index = 0.88 and EQ VAS = 79. These utilities are in line with those found in the present study: age‐adjusted mean EQ Index = 0.89 (*n* = 468), age‐adjusted mean EQ VAS = 78 (*n* = 477). Although the Swedish and Danish authors reported a decrease in utilities by 4% when severe actinic damage or previous SCC was present, this difference failed to reach statistical significance.[48](#jdv14703-bib-0048){ref-type="ref"} Moreover, the authors did not include patients with SCC, BCC and multiple diagnoses and could thus not assess the potential impact of disease progression.[48](#jdv14703-bib-0048){ref-type="ref"} On the other hand, the key findings of the present study can be used to approximate the impact of potential disease progression on QL by comparing patients with relatively benign AK to those having developed SCC and multiple diagnoses.

In addition, the present study has the benefit that several forms of NMSC and multiple diagnoses were assessed along with AK although a larger subgroup size might have been desirable, especially for the smallest subgroup of *n* = 31 patients with SCC only. A further limitation of the present study is its cross‐sectional design, which does not allow for longitudinal QL reassessment. The data are restricted to Germany, but the country‐specific EQ Index allows comparisons across countries. QL reference values for several European countries including Germany are available.[49](#jdv14703-bib-0049){ref-type="ref"}, [50](#jdv14703-bib-0050){ref-type="ref"}

ANCOVAs significantly showed that QL is correlated with age and differs between diagnoses. Older patients reported significantly lower QL than younger patients. The analyses showed a clear reduction in QL, when patients with tumour diagnoses (SCC, BCC, or SCC plus BCC) are compared to those with AK only (4--9%). More importantly, the comparison of patients with AK to those with AK plus SCC demonstrates a significant decline in QL (7%). This may serve as initial evidence that progression from AK to SCC is accompanied by a decrease in QL. This is not automatically evident, because progression to SCC does not immediately mean gross functional impairment, but patients still perceive it as meaningful and detrimental. Therefore, dermatologists are advised to pay full attention to AK and initiate treatments with highest clearance probabilities as early as possible. Treatment of AK should be performed with both, the intention to prevent SCC and to preserve and restore QL in patients. To observe these effects in more detail, a longitudinal study is warranted, following up patients with AK progressing to SCC over time. Moreover, further analyses are planned within the present data set focusing on the predictors of QL, such as lesion site (especially sites of high cosmetic importance), number of lesions and treatment types. Another important research question for the future is a thorough comparison between NMSC/AK patients with reference data from the general population and from other patient groups.[51](#jdv14703-bib-0051){ref-type="ref"}, [52](#jdv14703-bib-0052){ref-type="ref"}, [53](#jdv14703-bib-0053){ref-type="ref"}, [54](#jdv14703-bib-0054){ref-type="ref"}

In conclusion, we analysed QL data from 1184 patients with NMSC and AK, which makes this study one of the largest reported PROM studies in the field of dermatology. Our results suggest that disease progression from AK to SCC is associated with a significant reduction in QL. This finding should be interpreted as a valid reason to treat AK with due diligence and to acknowledge the fact that NMSC, albeit seldom life‐threatening, has considerable impact on patients' health and well‐being.
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